| CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 414 | 2012 |
| Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease [RETIRED] Report of the Quality Standards Subcommittee of the American Academy of Neurology TA Zesiewicz, KL Sullivan, I Arnulf, KR Chaudhuri, JC Morgan, ... Neurology 74 (11), 924-931, 2010 | 374 | 2010 |
| Drug-induced tremors JC Morgan, KD Sethi The Lancet Neurology 4 (12), 866-876, 2005 | 231 | 2005 |
| National randomized controlled trial of virtual house calls for Parkinson disease CA Beck, DB Beran, KM Biglan, CM Boyd, ER Dorsey, PN Schmidt, ... Neurology 89 (11), 1152-1161, 2017 | 205 | 2017 |
| Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced experimental … M Ahuja, NA Kaidery, L Yang, N Calingasan, N Smirnova, A Gaisin, ... Journal of Neuroscience 36 (23), 6332-6351, 2016 | 191 | 2016 |
| Nintendo Wii rehabilitation (“Wii-hab”) provides benefits in Parkinson's disease NB Herz, SH Mehta, KD Sethi, P Jackson, P Hall, JC Morgan Parkinsonism & related disorders 19 (11), 1039-1042, 2013 | 179 | 2013 |
| Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial K Kieburtz, BC Tilley, JJ Elm, D Babcock, R Hauser, GW Ross, ... Jama 313 (6), 584-593, 2015 | 171 | 2015 |
| Switching ST udy of Kidney TRansplant PA tients with Tremor to LCP‐TacrO (STRATO): an open‐label, multicenter, prospective phase 3b study A Langone, SM Steinberg, R Gedaly, LK Chan, T Shah, KD Sethi, V Nigro, ... Clinical transplantation 29 (9), 796-805, 2015 | 115 | 2015 |
| Botulinum toxin A during pregnancy: a survey of treating physicians JC Morgan, SS Iyer, ET Moser, C Singer, KD Sethi Journal of Neurology, Neurosurgery & Psychiatry 77 (1), 117-119, 2006 | 104 | 2006 |
| Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial GU Höglinger, I Litvan, N Mendonca, D Wang, H Zheng, ... The Lancet Neurology 20 (3), 182-192, 2021 | 102 | 2021 |
| Upregulation of GPR109A in Parkinson’s disease C Wakade, R Chong, E Bradley, B Thomas, J Morgan PloS one 9 (10), e109818, 2014 | 91 | 2014 |
| Association between change in body mass index, unified Parkinson’s disease rating scale scores, and survival among persons with Parkinson disease: secondary analysis of … AMA Wills, A Pérez, J Wang, X Su, J Morgan, SS Rajan, MA Leehey, ... JAMA neurology 73 (3), 321-328, 2016 | 89 | 2016 |
| Transient ischemic attack and stroke associated with sildenafil (Viagra) use JC Morgan, M Alhatou, J Oberlies, KC Johnston Neurology 57 (9), 1730-1731, 2001 | 87 | 2001 |
| Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial B Bluett, DM Togasaki, D Mihaila, M Evatt, M Rezak, S Jain, ... Jama 326 (10), 926-939, 2021 | 80 | 2021 |
| Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment SH Mehta, JC Morgan, KD Sethi CNS spectrums 13 (S4), 6-11, 2008 | 79 | 2008 |
| Interprofessional education increases knowledge, promotes team building, and changes practice in the care of Parkinson's disease EV Cohen, R Hagestuen, G González-Ramos, HW Cohen, C Bassich, ... Parkinsonism & Related Disorders 22, 21-27, 2016 | 77 | 2016 |
| Biomarkers in Parkinson’s disease JC Morgan, SH Mehta, KD Sethi Current neurology and neuroscience reports 10, 423-430, 2010 | 77 | 2010 |
| Reversible corpus callosum lesion in legionnaires’ disease JC Morgan, R Cavaliere, VC Juel Journal of Neurology, Neurosurgery & Psychiatry 75 (4), 651-654, 2004 | 70 | 2004 |
| Neuropsychiatric symptoms in dementia: considerations for pharmacotherapy in the USA SV Phan, S Osae, JC Morgan, M Inyang, SC Fagan Drugs in R&D 19, 93-115, 2019 | 69 | 2019 |
| Drug-induced movement disorders SH Mehta, JC Morgan, KD Sethi Neurol Clin 33 (1), 153-174, 2015 | 68 | 2015 |
